A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

Prior treatment

• Treatment with any marketed or investigational drug with a glucagon-like peptide-1 (GLP-1) receptor agonist mechanism within 1 year prior to screening.
• Self-reported or documented body weight change of ≥ 5 kg within 3 months prior to screening.
• History of or current severe gastrointestinal disease or prior major gastrointestinal surgery.
• Clinically significant active or unstable severe major depressive disorder or other severe psychiatric disorders within 2 years prior to screening; or any history of suicide attempt.

Other illness

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
• History of or current secondary hypertension.
• History of or current type 1 or type 2 diabetes mellitus.
• History of or current malignancy within the past 5 years, except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.
• History of or current major cardiovascular or cerebrovascular disease.

Other

• Office seated systolic blood pressure (SBP) ≥ 170 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg at screening or baseline, or presence of a hypertensive emergency.
• A decrease in office seated SBP of ≥ 20 mmHg or a decrease in office seated DBP of ≥ 10 mmHg at baseline compared with screening.
• Presence of orthostatic hypotension at screening, defined as a decrease in office SBP of ≥ 15 mmHg or DBP of ≥ 7 mmHg upon transition from the seated to standing position.
• A difference of ≥ 20 mmHg in office seated SBP between the left and right upper arms at screening or baseline.
• Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at screening, or a positive response to Item 9.
• Pregnant or breastfeeding women; or men or women of childbearing potential who are unwilling to use highly effective contraception throughout the study and for 3 months after the last dose, or who plan to conceive, donate sperm, or donate oocytes during this period; or women with a positive pregnancy test at screening.

• Male or female participants aged 18 to 75 years (inclusive) at the time of screening.
• Body mass index (BMI) ≥ 24 kg/m² at screening.
• Diagnosed with primary hypertension, with office seated systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg at both screening and baseline.
• Either treatment-naïve to antihypertensive therapy for ≥ 30 days prior to screening, or receiving a stable dose for ≥ 30 days of one or two of the following classes of antihypertensive medications: renin-angiotensin system inhibitors (ARB/ACEI), calcium channel blockers (CCB), or diuretics.
• Has at least one self-reported history of unsuccessful weight loss through dietary control.
• Willing and able to maintain a stable residence and remain contactable throughout the study, and to adhere to regular lifestyle routines as well as dietary and exercise management during the trial.
• Has a full understanding of the study procedures, is able to communicate effectively with the investigator, understands and is willing to comply with all study requirements, and voluntarily provides written informed consent.